ReviewJournal of infection and public health2021
COVID-19 and the lungs: A review.
Review in Journal of infection and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Correlations Between Oxygen Consumption, Ventilatory Mechanics, and Lung Ultrasound in Individuals with Post-COVID Syndrome.International journal of environmental research and public health · 2025Article
- Lung Volume Change Assessment in Moderate and Severe COVID-19 Using CT Volumetry.Diagnostics (Basel, Switzerland) · 2025Article
- An engineered miniACE2 protein secreted by mesenchymal stromal cells effectively neutralizes multiple SARS-CoV- 2 variants in vitro.Molecular medicine (Cambridge, Mass.) · 2025Article
- Heparan sulfate proteoglycans remodel SARS-CoV-2 spike conformation to allow integrin interaction and infection of endothelial cells.Frontiers in cellular and infection microbiology · 2025Article
- Bacterial sepsis causes more dramatic pathogenetic changes in the Th1 pathway than does viral (COVID-19) sepsis: a prospective observational study of whole blood transcriptomes.Virology journal · 2024Observational
- Ginseng and ginsenosides on cardiovascular and pulmonary diseases; Pharmacological potentials for the coronavirus (COVID-19).Journal of ginseng research · 2024Review
- Epidemiological profile of patients hospitalized with Crohn's disease due to severe acute respiratory infection during the COVID-19 pandemic: a 2-year report from Brazil.Frontiers in medicine · 2024Article
- Causal associations between severe COVID-19 and diseases of seven organs: a proteome-wide mendelian randomization study.Frontiers in genetics · 2024Article
- A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4Journal of virology · 2023Article
- Inflammation and Venous Thromboembolism in Hospitalized Patients with COVID-19.Diagnostics (Basel, Switzerland) · 2023Article
- Impact of COVID-19 on Physical Fitness in Central Indian Athletes Aged 20-30 Years: A Cross-Sectional Pilot Study.Cureus · 2023Article
- Radiological and Functional Pulmonary Evolution in Post-COVID-19 Patients: An Observational Study.Diseases (Basel, Switzerland) · 2023Article
- Outcome of In-Hospital Cardiac Arrest among Patients with COVID-19: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Ultrasound-Driven On-Demand Transient Triboelectric Nanogenerator for Subcutaneous Antibacterial Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- The influence of COVID-19 on colorectal cancer was investigated using bioinformatics and systems biology techniques.Frontiers in medicine · 2023Article
- MMP-9/BDNF ratio predicts more severe COVID-19 outcomes.International journal of medical sciences · 2022Article
- Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) attacks pulmonary alveolar cells via angiotensin-converting enzyme 2 (ACE2) receptors and causes pulmonary infections that result in coronavirus disease (COVID-19), inducing immune responses that can result in severe pneumonia. We reviewed the clinical experiences of lung diseases during the COVID-19 pandemic to offer insights into the adaptations made by experts in the diagnosis and treatment of these comorbidities. Various lung comorbidities increase the severity of COVID-19 and associated mortality by amplifying ACE2 expression. Additionally, the COVID-19 pandemic has changed the use of routine diagnostic pulmonary imaging methods, making chest sonography scoring the most convenient, as it can be conducted bedside. Treatment protocols for SARS-CoV-2 infection and the underlying lung diseases are also affected owing to potential interactions. The optimal diagnostic methods and treatment protocols for lung diseases have been adapted worldwide to increase survival rates and attenuate acute lung injuries during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.